How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatmen...

Full description

Bibliographic Details
Main Authors:	Viola Cogliati, Serena Capici, Francesca Fulvia Pepe, Pierluigi di Mauro, Francesca Riva, Federica Cicchiello, Claudia Maggioni, Nicoletta Cordani, Maria Grazia Cerrito, Marina Elena Cazzaniga
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Life
Subjects:	metastatic breast cancer CDK4/6 inhibitors therapy resistance treatment sequencing
Online Access:	https://www.mdpi.com/2075-1729/12/3/378

Similar Items

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
by: Nicoletta Cordani, et al.
Published: (2023-11-01)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
by: Joseph J. Zhao, et al.
Published: (2023-09-01)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
by: Marina Elena Cazzaniga, et al.
Published: (2022-08-01)

Metronomic Chemotherapy
by: Marina Elena Cazzaniga, et al.
Published: (2021-05-01)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
by: Ioana-Miruna Stanciu, et al.
Published: (2023-03-01)

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer
by: Elena Peruzzi, et al.
Published: (2023-11-01)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
by: Daniele Presti, et al.
Published: (2019-08-01)

Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective
by: Marek Ziobro, et al.
Published: (2023-02-01)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
by: Alessandra Fabi, et al.
Published: (2022-09-01)

Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient
by: Bo Pan, et al.
Published: (2022-12-01)

Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
by: Constanze Elfgen, et al.
Published: (2021-11-01)

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
by: Ni Zeng, et al.
Published: (2023-06-01)

Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer
by: Loreto Domínguez Senín, et al.
Published: (2024-01-01)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
by: Alberto D’Angelo, et al.
Published: (2022-09-01)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
by: Jin Sun Lee, et al.
Published: (2022-06-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
by: Danyang Ji, et al.
Published: (2023-08-01)

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
by: Fausto Petrelli, et al.
Published: (2023-10-01)

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
by: Emily Jiggens, et al.
Published: (2021-10-01)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
by: Stefania Crucitta, et al.
Published: (2023-02-01)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
by: Masahiro Ohara, et al.
Published: (2021-03-01)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
by: Debora de Melo Gagliato, et al.
Published: (2020-09-01)

CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01)

Identifying Cancers Impacted by CDK8/19
by: Igor B. Roninson, et al.
Published: (2019-08-01)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
by: Michela Piezzo, et al.
Published: (2020-09-01)

Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer
by: Alice Ilari, et al.
Published: (2024-01-01)

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
by: Marina Elena Cazzaniga, et al.
Published: (2023-10-01)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
by: Michela Piezzo, et al.
Published: (2020-09-01)

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
by: Alicia Milagros de Luna Aguilar, et al.
Published: (2023-09-01)

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
by: Dongqing Pu, et al.
Published: (2024-01-01)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
by: Serena Capici, et al.
Published: (2022-07-01)

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
by: Yan Mao, et al.
Published: (2023-01-01)

Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
by: Andreea-Iuliana Miron, et al.
Published: (2023-06-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)

Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay
by: Jing Li, et al.
Published: (2019-10-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer
by: A. Yu. Goryainova, et al.
Published: (2022-06-01)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
by: Kamal Pandey, et al.
Published: (2020-11-01)

Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
by: Nadia Ashai, et al.
Published: (2023-03-01)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
by: Lucrezia Raimondi, et al.
Published: (2021-04-01)